Tabula Rasa HealthCare (NASDAQ:TRHC) Stock Rating Upgraded by BidaskClub

Tabula Rasa HealthCare (NASDAQ:TRHC) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday, BidAskClub reports.

TRHC has been the topic of a number of other reports. Zacks Investment Research downgraded shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. Piper Jaffray Companies increased their price objective on shares of Beigene to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, May 9th. Guggenheim began coverage on shares of Patterson Companies in a research note on Wednesday, April 17th. They set a “neutral” rating and a $23.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of CytomX Therapeutics in a research note on Monday, May 13th. They set an “overweight” rating and a $21.00 price objective on the stock. Finally, TheStreet downgraded shares of Twin Disc from a “b-” rating to a “c+” rating in a research note on Tuesday, June 11th. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Tabula Rasa HealthCare presently has an average rating of “Buy” and an average price target of $82.12.

Shares of Tabula Rasa HealthCare stock opened at $54.25 on Friday. The firm has a market capitalization of $1.19 billion, a P/E ratio of 271.25 and a beta of 1.62. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.80 and a quick ratio of 1.73. Tabula Rasa HealthCare has a 12-month low of $40.86 and a 12-month high of $91.16. The business’s 50-day moving average price is $48.02.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14). The firm had revenue of $60.96 million for the quarter, compared to the consensus estimate of $59.24 million. Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%. On average, research analysts forecast that Tabula Rasa HealthCare will post -0.55 earnings per share for the current year.

In other news, CEO Calvin H. Knowlton sold 8,270 shares of the stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $53.68, for a total value of $443,933.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gordon Tunstall sold 1,000 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $52.60, for a total transaction of $52,600.00. The disclosure for this sale can be found here. Insiders sold 50,270 shares of company stock valued at $2,457,654 in the last three months. Company insiders own 11.80% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Handelsbanken Fonder AB acquired a new stake in shares of Tabula Rasa HealthCare during the 2nd quarter worth approximately $6,241,000. Marshall Wace North America L.P. grew its position in shares of Tabula Rasa HealthCare by 156.2% during the 1st quarter. Marshall Wace North America L.P. now owns 17,575 shares of the company’s stock worth $992,000 after buying an additional 10,715 shares during the period. Belpointe Asset Management LLC acquired a new stake in shares of Tabula Rasa HealthCare during the 1st quarter worth approximately $172,000. Citigroup Inc. grew its position in shares of Tabula Rasa HealthCare by 2,337.1% during the 1st quarter. Citigroup Inc. now owns 309,588 shares of the company’s stock worth $17,467,000 after buying an additional 296,885 shares during the period. Finally, Meitav Dash Investments Ltd. grew its position in shares of Tabula Rasa HealthCare by 2.7% during the 1st quarter. Meitav Dash Investments Ltd. now owns 38,000 shares of the company’s stock worth $2,130,000 after buying an additional 1,000 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Read More: Marijuana Stocks

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.